These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9773912)

  • 1. Tracheal aspirate surface tension in babies with hyaline membrane disease: effects of synthetic surfactant replacement.
    McMillan DD; Singhal N; Shukla AK; Schürch S
    Pediatr Pulmonol; 1998 Sep; 26(3):173-82. PubMed ID: 9773912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biophysical models in investigations of exogenous surfactant activities on the surface tension and their theurapeutic effectiveness].
    Todorov R; Iordanova A; Georgiev GA; Petkova Kh; Stoimenova E; Georgieva R; Khristova E; Vasiliev Kh; Lalchev Z
    Akush Ginekol (Sofiia); 2007; 46 Suppl 1():29-36. PubMed ID: 18175392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elastase activity and surfactant protein concentration in tracheal aspirates from neonates receiving synthetic surfactant.
    Gerdes J; Whitsett J; Long W
    J Pediatr; 1992 Feb; 120(2 Pt 2):S34-9. PubMed ID: 1735850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surface tension of therapeutic surfactants (exosurf neonatal, infasurf, and survanta) as evaluated by standard methods and criteria.
    Scarpelli EM; David E; Cordova M; Mautone AJ
    Am J Perinatol; 1992; 9(5-6):414-9. PubMed ID: 1418146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome.
    Dechant KL; Faulds D
    Drugs; 1991 Nov; 42(5):877-94. PubMed ID: 1723378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early or selective surfactant (colfosceril palmitate, Exosurf) for intubated babies at 26 to 29 weeks gestation. A European double-blind trial with sequential analysis. European Exosurf Study Group.
    Online J Curr Clin Trials; 1992 Nov; Doc No 28():[3886 words; 47 paragraphs]. PubMed ID: 1343614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surfactant replacement therapy in neonates less than 32 weeks gestation: effect on neonatal intensive care resource utilization.
    Diwaker K; Roberts S; John E
    J Paediatr Child Health; 1993 Dec; 29(6):434-7. PubMed ID: 8286159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosurf rescue surfactant improves high ventilation-perfusion mismatch in respiratory distress syndrome.
    Billman D; Nicks J; Schumacher R
    Pediatr Pulmonol; 1994 Nov; 18(5):279-83. PubMed ID: 7898965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group.
    Long W; Corbet A; Cotton R; Courtney S; McGuiness G; Walter D; Watts J; Smyth J; Bard H; Chernick V
    N Engl J Med; 1991 Dec; 325(24):1696-703. PubMed ID: 1944470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory mechanics before and after late artificial surfactant rescue.
    Todd DA; Choukroun ML; Fayon M; Kays C; Guénard H; Galpérine I; Demarquez JL
    J Paediatr Child Health; 1995 Dec; 31(6):532-6. PubMed ID: 8924306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surfactant therapy for hyaline membrane disease: the Chandigarh experience.
    Narang A; Kumar P; Dutta S; Kumar R
    Indian Pediatr; 2001 Jun; 38(6):640-6. PubMed ID: 11418729
    [No Abstract]   [Full Text] [Related]  

  • 12. Lung mechanics and gas exchange in ventilated preterm infants during treatment of hyaline membrane disease with multiple doses of artificial surfactant (Exosurf).
    Pfenninger J; Aebi C; Bachmann D; Wagner BP
    Pediatr Pulmonol; 1992 Sep; 14(1):10-5. PubMed ID: 1437337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial clinical trial of EXOSURF, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease.
    Phibbs RH; Ballard RA; Clements JA; Heilbron DC; Phibbs CS; Schlueter MA; Sniderman SH; Tooley WH; Wakeley A
    Pediatrics; 1991 Jul; 88(1):1-9. PubMed ID: 2057244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in immediate and short-term outcome of premature neonates treated with two types of exogenous surfactant preparation.
    Malathi I; Ng KC
    Ann Acad Med Singap; 1995 Nov; 24(6):781-4. PubMed ID: 8838980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Static respiratory compliance in the newborn. III: Early changes after exogenous surfactant treatment.
    Stenson BJ; Glover RM; Parry GJ; Wilkie RA; Laing IA; Tarnow-Mordi WO
    Arch Dis Child Fetal Neonatal Ed; 1994 Jan; 70(1):F19-24. PubMed ID: 8117122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary mechanics in ventilated preterm infants with respiratory distress syndrome after exogenous surfactant administration: a comparison between two surfactant preparations.
    Choukroun ML; Llanas B; Apere H; Fayon M; Galperine RI; Guenard H; Demarquez JL
    Pediatr Pulmonol; 1994 Nov; 18(5):273-8. PubMed ID: 7898964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome.
    Hudak ML; Martin DJ; Egan EA; Matteson EJ; Cummings NJ; Jung AL; Kimberlin LV; Auten RL; Rosenberg AA; Asselin JM; Belcastro MR; Donohue PK; Hamm CR; Jansen RD; Brody AS; Riddlesberger MM; Montgomery P
    Pediatrics; 1997 Jul; 100(1):39-50. PubMed ID: 9200358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants.
    Hall SB; Venkitaraman AR; Whitsett JA; Holm BA; Notter RH
    Am Rev Respir Dis; 1992 Jan; 145(1):24-30. PubMed ID: 1731593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, randomized, placebo-controlled Canadian multicenter trial of two doses of synthetic surfactant or air placebo in 224 infants weighing 500 to 749 grams with respiratory distress syndrome. Canadian Exosurf Neonatal Study Group.
    Smyth J; Allen A; MacMurray B; Peliowski A; Sankaran K; Volberg F; Shukla A; Long W
    J Pediatr; 1995 May; 126(5 Pt 2):S81-9. PubMed ID: 7745516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country.
    da Costa DE; Pai MG; Al Khusaiby SM
    Pediatr Pulmonol; 1999 May; 27(5):312-7. PubMed ID: 10344709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.